Literature DB >> 6415174

Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge.

J Y Niederkorn, J W Streilein.   

Abstract

Intracameral inoculation of allogeneic P815 mastocytoma cells (DBA/2) into BALB/c mice resulted in progressively growing intraocular tumors. Intraocular tumor cells disseminated rapidly to the spleen and cervical lymph nodes, yet extraocular nests of tumor cells never developed into fulminant tumors. Further experiments showed that tumor cells were continuously seeded from the primary intraocular tumor and were rapidly cleared from extraocular sites. Hosts harboring intraocular P815 mastocytomas rejected tumorigenic doses of P815 cells inoculated subcutaneously or even into the contralateral anterior chamber. This systemic tumor immunity was found to be radiosensitive and T cell dependent. Spleen cells from animals with progressively growing intraocular tumors protected recipient mice challenged with intracamerally inoculated tumor cells and thus suggests that a cell-mediated mechanism is the underlying basis for this form of tumor immunity. The data indicate that mice harboring progressively growing intraocular tumors develop a potent state of "concomitant immunity," that prevents the development of metastases, yet is ineffective in controlling the primary tumor.

Entities:  

Mesh:

Year:  1983        PMID: 6415174

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination.

Authors:  Rodolfo D Vicetti Miguel; Thomas L Cherpes; Leah J Watson; Kyle C McKenna
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

Review 2.  Influence of immune privilege on ocular tumor development.

Authors:  Kyle C McKenna; Peter W Chen
Journal:  Ocul Immunol Inflamm       Date:  2010-04       Impact factor: 3.070

3.  A caveat for T cell transfer studies: generation of cytotoxic anti-Thy1.2 antibodies in Thy1.1 congenic mice given Thy1.2+ tumors or T cells.

Authors:  Kyle C McKenna; Rodolfo D Vicetti Miguel; Kelly M Beatty; Richard A Bilonick
Journal:  J Leukoc Biol       Date:  2010-10-19       Impact factor: 4.962

4.  Incomplete activation of lymphokine-producing T cells by alloantigenic intraocular tumours in anterior chamber-associated immune deviation.

Authors:  Y Bando; B R Ksander; J W Streilein
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

Review 5.  Ocular immune privilege and CTL tolerance.

Authors:  Kyle C McKenna; Judith A Kapp
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.

Authors:  Tonia Mazzarella; Valeria Cambiaghi; Nathalie Rizzo; Lorenzo Pilla; Danilo Parolini; Elena Orsenigo; Annalisa Colucci; Giulio Modorati; Claudio Doglioni; Giorgio Parmiani; Cristina Maccalli
Journal:  Cancer Immunol Immunother       Date:  2011-12-30       Impact factor: 6.968

Review 7.  The immune system in cancer metastasis: friend or foe?

Authors:  Louise M E Janssen; Emma E Ramsay; Craig D Logsdon; Willem W Overwijk
Journal:  J Immunother Cancer       Date:  2017-10-17       Impact factor: 13.751

8.  Influence of CD8+ T regulatory cells on intraocular tumor development.

Authors:  Kyle C McKenna; Dana M Previte
Journal:  Front Immunol       Date:  2012-09-28       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.